We therefore explored the activation of the MAPK pathway in this cohort of primary and recurrent craniopharyngiomas, by immunohistochemistry against phosphorylated (p)-ERK1/2, a read-out of the activated pathway [22]. Here, MAPK3 is linked to craniopharyngioma.